Analysts See $-0.57 EPS for Sarepta Therapeutics, Inc. (SRPT)

June 15, 2018 - By Vivian Currie

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in 2018 Q1. Its down 0.25, from 1.22 in 2017Q4. It fall, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Brown Brothers Harriman And holds 25,370 shares. First Allied Advisory, a Missouri-based fund reported 7,064 shares. Fuller & Thaler Asset Mngmt reported 0.13% stake. Susquehanna Gp Ltd Liability Partnership holds 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 306,589 shares. Peddock Advisors Ltd Company reported 54 shares. Moreover, Prudential Fincl has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 53,215 shares. Sphera Funds Mngmt Limited invested 2.8% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Wells Fargo Mn reported 628,048 shares or 0.01% of all its holdings. Prelude Capital Ltd Liability Co owns 21,449 shares for 0.12% of their portfolio. State Bank Of America De holds 0% or 101,845 shares in its portfolio. Dupont Capital Management Corp has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Swiss Bancshares invested in 106,500 shares. Qs Investors Ltd Liability accumulated 2,664 shares. Cambridge Investment Rech holds 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 10,551 shares. Teacher Retirement System Of Texas, Texas-based fund reported 13,566 shares.

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.57 EPS on July, 18.They anticipate $0.58 EPS change or 50.43 % from last quarter’s $-1.15 EPS. After having $-0.44 EPS previously, Sarepta Therapeutics, Inc.’s analysts see 29.55 % EPS growth. The stock increased 2.08% or $2.01 during the last trading session, reaching $98.78. About 1.65M shares traded or 32.02% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 15, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 16 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 14 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Sarepta Therapeutics had 27 analyst reports since January 3, 2018 according to SRatingsIntel. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Leerink Swann on Friday, January 19. The stock has “Buy” rating by Leerink Swann on Tuesday, May 15. The rating was initiated by RBC Capital Markets with “Buy” on Monday, January 22. Piper Jaffray maintained the shares of SRPT in report on Friday, March 2 with “Buy” rating. As per Monday, March 12, the company rating was maintained by H.C. Wainwright. Piper Jaffray maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Monday, March 12 with “Buy” rating. The firm has “Overweight” rating by JP Morgan given on Wednesday, March 14. The firm has “Buy” rating by Nomura given on Tuesday, June 5. On Thursday, May 3 the stock rating was downgraded by Oppenheimer to “Hold”. The firm has “Outperform” rating by Credit Suisse given on Friday, May 4.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.47 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Streetinsider.com which released: “Sarepta Therapeutics (SRPT) Announces Long-term Strategic Manufacturing Partnership with Brammer Bio” on June 13, 2018, also Seekingalpha.com with their article: “EMA’s advisory committee thumbs down on Sarepta’s Exondys” published on June 01, 2018, Nasdaq.com published: “Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene …” on June 13, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Bizjournals.com and their article: “Biogen’s head of late-stage trials leaves for Sarepta” published on June 07, 2018 as well as Investorplace.com‘s news article titled: “7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.” with publication date: June 13, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: